University Of Vermont Medical Center
- Type
- Teaching hospital
- Where
- BURLINGTON, VT
- Medicare CCN
- 470003
- Received
- $3,235,635 in 744 records, 2020 ($65,300 general, $3,170,334 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE UNIVERSITY OF VERMONT MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: UNIVERSITY OF VERMONT MEDICAL CENTER INC., THE Fuzzy (name and state)
- Nonprofit: UNIVERSITY OF VERMONT MEDICAL CENTER INC Fuzzy (name and state)
- Trademark owner: The University of Vermont Medical Center Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 17 | $65,300 |
| 2020 | Research payment | 727 | $3,170,334 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 727 | $3,170,334 |
| Grant | 3 | $31,000 |
| Education | 4 | $26,990 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $2,548 |
| Gift | 4 | $2,511 |
| Space rental or facility fees (teaching hospital only) | 3 | $1,750 |
| Charitable Contribution | 1 | $500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $66,862 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2020 | |
| 2020-12-31 | Philips North America LLC | $15,360 | Research payment | Cash or cash equivalent | Achieva 3 0TX R5 Device, Devices | 2020 | |
| 2020-12-31 | Philips North America LLC | $13,467 | Research payment | Cash or cash equivalent | (6260) Ingenia 3 0T R5 Device, Neurology | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $2,739 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2020 |
| 2020-12-31 | EMD Serono, Inc. | $68 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-12-31 | Masimo Corporation | $32 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-30 | Merck Sharp & Dohme LLC | $8,907 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-12-30 | Merck Sharp & Dohme LLC | $1,560 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-12-24 | Janssen Research & Development, LLC | $18,147 | Research payment | Cash or cash equivalent | Multicenter, randomized, double-blind, parallel-group extension study AC-058B201 to investigate the long-term, tolerabil | 2020 | |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $2,305 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-23 | EMD Serono, Inc. | $5,469 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-12-23 | EMD Serono, Inc. | $3,900 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $2,799 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-23 | EMD Serono, Inc. | $2,340 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-12-23 | Novo Nordisk AS | $41 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-22 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-12-22 | SEAGEN INC. | $15,974 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-22 | SEAGEN INC. | $3,500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-22 | Novo Nordisk AS | $3,058 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $2,745 | Research payment | Cash or cash equivalent | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-22 | Roche Products Limited | $939 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-12-22 | Novo Nordisk AS | $900 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $415 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $140 | Research payment | Cash or cash equivalent | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-21 | EMD Serono, Inc. | $1,146 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previ | 2020 |
| 2020-12-21 | EMD Serono, Inc. | $683 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previ | 2020 |
| 2020-12-21 | Pharmacyclics LLC, an AbbVie Company | $476 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-12-21 | AKEBIA THERAPEUTICS INC | $265 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-12-21 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-17 | Alexion Pharmaceuticals, Inc. | $43,096 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-12-17 | Roche Products Limited | $3,069 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-12-17 | AKEBIA THERAPEUTICS INC | $30 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-12-16 | Intercept Pharmaceuticals, Inc. | $5,208 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII YOSEMITE | 2020 |
| 2020-12-15 | Medtronic Vascular, Inc. | $378 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $3,531 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $2,131 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $1,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $502 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $401 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-08 | AKEBIA THERAPEUTICS INC | $11,856 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-12-08 | Novo Nordisk AS | $41 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $1,658 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-12-07 | SANOFI US SERVICES INC. | $538 | Research payment | Cash or cash equivalent | An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopa | 2020 | |
| 2020-12-03 | SANOFI PASTEUR INC. | $15,410 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-12-02 | ABBVIE INC. | $629 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-12-01 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | CoreValve CAS | 2020 | |
| 2020-11-30 | Novo Nordisk AS | $1,451 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-11-30 | EMD Serono, Inc. | $68 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-11-24 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2020 |
| 2020-11-24 | Novo Nordisk AS | $415 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-11-20 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-19 | Grifols Biologicals LLC | $1,500 | Research payment | Cash or cash equivalent | Flebogamma DIF Biological, Immnunology | A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Eff | 2020 |
| 2020-11-18 | Gyrus ACMI, Inc. | $7,950 | Research payment | Cash or cash equivalent | SVS Device, EndoTherapy | Spiration Valve System Post-Market Registry Study | 2020 |
| 2020-11-16 | Medtronic Vascular, Inc. | $2,137 | Research payment | Cash or cash equivalent | ECG Belt | 2020 | |
| 2020-11-16 | Janssen Research & Development, LLC | $1,865 | Research payment | Cash or cash equivalent | A multi center prospective long term observational registry of pediatric patients with IBS | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | CAP2 | 2020 |
| 2020-11-11 | Clovis Oncology, Inc. | $5,156 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | 2020 |
| 2020-11-11 | Medtronic Vascular, Inc. | $3,298 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-11-11 | Medtronic Vascular, Inc. | $3,298 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-11-11 | Abbott Laboratories | $1,607 | Research payment | Cash or cash equivalent | Agilis HisPro Device, Cardiac Arrhythmias and Heart Failure | Physiologic Pacing Registry | 2020 |
| 2020-11-11 | Novo Nordisk AS | $41 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-11-10 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-11-10 | Orion Corporation | $2,000 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-11-10 | Abbott Laboratories | $100 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-11-09 | SANOFI US SERVICES INC. | $23,530 | Research payment | Cash or cash equivalent | Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menop | 2020 | |
| 2020-11-09 | American Regent | $1,124 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $247 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $209 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $188 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $182 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $70 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $61 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $56 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $47 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $47 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $40 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $34 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $34 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $14 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $11 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $4 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-11-05 | Alexion Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-05 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2020 |
| 2020-11-03 | Orion Corporation | $1,013 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2020 | |
| 2020-11-02 | Boston Scientific Corporation | $1,618 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-11-02 | AKEBIA THERAPEUTICS INC | $1,500 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-11-02 | Boston Scientific Corporation | $1,137 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $764 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-01 | Biogen, Inc. | $398 | Research payment | In-kind items and services | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyot | 2020 | |
| 2020-10-30 | EMD Serono, Inc. | $68 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-10-29 | Medtronic Vascular, Inc. | $9,770 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-10-29 | Medtronic Vascular, Inc. | $9,770 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-10-29 | Intercept Pharmaceuticals, Inc. | $7,227 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-10-29 | Novo Nordisk AS | $3,773 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-10-29 | Novo Nordisk AS | $1,950 | Research payment | Cash or cash equivalent | NN9931-4296 | 2020 | |
| 2020-10-29 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-10-29 | AstraZeneca UK Limited | $628 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2020 | |
| 2020-10-28 | Blue Earth Diagnostics | $4,005 | Research payment | In-kind items and services | Axumin Drug, Diagnostic Imaging | Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy | 2020 |
| 2020-10-28 | Abbott Laboratories | $2,691 | Research payment | Cash or cash equivalent | Amplatzer Amulet LAAO Device, Vascular | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2020 |
| 2020-10-23 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-852 | 2020 |
| 2020-10-23 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Research payment | Cash or cash equivalent | NATPARA (PARATHYROID HORMONE) Drug, INTERNAL MEDICINE | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2020 |
| 2020-10-16 | Medtronic Vascular, Inc. | $20,216 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2020 |
| 2020-10-15 | American Regent | $10,667 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-10-15 | Medtronic Vascular, Inc. | $3,154 | Research payment | Cash or cash equivalent | ECG Belt | 2020 | |
| 2020-10-15 | Medtronic Vascular, Inc. | $1,570 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve EUS | 2020 |
| 2020-10-14 | United Therapeutics Corporation | $2,247 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2020 |
| 2020-10-14 | Gyrus ACMI, Inc. | $974 | Research payment | Cash or cash equivalent | SVS Device, EndoTherapy | A Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val | 2020 |
| 2020-10-13 | SANOFI US SERVICES INC. | $2,500 | Research payment | Cash or cash equivalent | An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopa | 2020 | |
| 2020-10-13 | Merck Sharp & Dohme LLC | $287 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2020 |
| 2020-10-08 | Genentech, Inc. | $10,557 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII YOSEMITE | 2020 |
| 2020-10-08 | Medtronic Vascular, Inc. | $3,733 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2020 |
| 2020-10-08 | Medtronic Vascular, Inc. | $3,733 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2020 |
| 2020-10-08 | AstraZeneca UK Limited | $1,920 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2020 | |
| 2020-10-08 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-10-06 | AstraZeneca Pharmaceuticals LP | $743,405 | Research payment | Cash or cash equivalent | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2020 | |
| 2020-10-06 | Medical Device Business Services, Inc. | $30,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-06 | United Therapeutics Corporation | $297 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-10-05 | Boston Scientific Corporation | $6,491 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-10-04 | Medtronic, Inc. | $7,912 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-10-04 | Medtronic, Inc. | $343 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-10-04 | Medtronic, Inc. | $109 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-10-04 | Medtronic, Inc. | $75 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-10-01 | EMD Serono, Inc. | $2,500 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previ | 2020 |
| 2020-10-01 | Roche Products Limited | $2,500 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-10-01 | Roche Products Limited | $635 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-09-30 | Amryt Pharma Holdings Ltd | $215 | Research payment | Cash or cash equivalent | JUXTAPID Drug, Cardiology/Vascular Diseases | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-09-30 | EMD Serono, Inc. | $68 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-09-28 | ABBVIE INC. | $195 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-852 | 2020 |
| 2020-09-26 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-09-25 | Novo Nordisk AS | $150 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-25 | Novo Nordisk AS | $90 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-25 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-25 | Novo Nordisk AS | $22 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-25 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-25 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-25 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-09-24 | F. Hoffmann-La Roche AG | $16,468 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-09-24 | Novo Nordisk AS | $2,767 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-09-24 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-09-24 | Abbott Laboratories | $195 | Research payment | Cash or cash equivalent | Agilis HisPro Device, Cardiac Arrhythmias and Heart Failure | Physiologic Pacing Registry | 2020 |
| 2020-09-23 | Indivior Inc. | $30,104 | Research payment | Cash or cash equivalent | Understanding use of opioid medications by patients and non-patients | 2020 | |
| 2020-09-23 | Clovis Oncology, Inc. | $20,608 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | 2020 |
| 2020-09-23 | Clovis Oncology, Inc. | $5,109 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $4,302 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-09-23 | Clovis Oncology, Inc. | $2,600 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | 2020 |
| 2020-09-23 | Clovis Oncology, Inc. | $351 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | 2020 |
| 2020-09-22 | UCB SA | $5,850 | Research payment | Cash or cash equivalent | Briviact Drug, Neurology | MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM | 2020 |
| 2020-09-22 | UCB SA | $809 | Research payment | Cash or cash equivalent | Briviact Drug, Neurology | MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM | 2020 |
| 2020-09-22 | Novo Nordisk AS | $585 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-09-18 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve EUS | 2020 |
| 2020-09-17 | Intercept Pharmaceuticals, Inc. | $1,546 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-09-17 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | XALKORI Drug, ONCOLOGY | PHASE 1 SAFETY PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF02341066 A CMETHGFR SELECTIVE TYROSINE KINASE INHIBITOR AD | 2020 |
| 2020-09-17 | Alexion Pharmaceuticals, Inc. | $115 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-15 | Medtronic Vascular, Inc. | $1,050 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2020 |
| 2020-09-11 | Janssen Research & Development, LLC | $2,708 | Research payment | Cash or cash equivalent | A multi center prospective long term observational registry of pediatric patients with IBS | 2020 | |
| 2020-09-11 | Medtronic Vascular, Inc. | $2,700 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2020 |
| 2020-09-10 | Merck Sharp & Dohme LLC | $950 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-09-10 | Alexion Pharmaceuticals, Inc. | $245 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-10 | Alexion Pharmaceuticals, Inc. | $36 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Orion Corporation | $11,610 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-09-09 | United Therapeutics Corporation | $1,065 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $11,635 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-09-08 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Pa | 2020 |
| 2020-09-08 | Boston Scientific Corporation | $162 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-09-04 | American Regent | $1,500 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-09-03 | EMD Serono, Inc. | $68,053 | Research payment | Cash or cash equivalent | MSB0010718C | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biologic | 2020 |
| 2020-09-03 | EMD Serono, Inc. | $361 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(N | 2020 |
| 2020-09-03 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2020 |
The latest 200 records of 744.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Burlington, VT, county Chittenden County, VT, state Vermont; placed by its city name.
| Measure | Place (city or town) Burlington, VT | County Chittenden County, VT | State Vermont |
|---|---|---|---|
| Population B01003 | 44,675 | 169,758 | 647,106 |
| Population, 2020 census P1 | 44,743 | 168,323 | 643,077 |
| Median age B01002 | 26.8 | 37.3 | 43.1 |
| Under 18 B01001 | 11.1% | 17.2% | 17.9% |
| 65 and over B01001 | 12.1% | 16.9% | 21.4% |
| Households B11001 | 17,504 | 71,456 | 273,416 |
| Foreign born B05002 | 7.1% | 7.9% | 4.3% |
| Median household income B19013 | $71,109 | $96,759 | $81,203 |
| Median family income B19113 | $130,243 | $131,883 | $105,211 |
| Per capita income B19301 | $40,192 | $52,322 | $46,500 |
| Poverty rate B17001 | 20.5% | 9.7% | 10.1% |
| Unemployment rate B23025 | 4.3% | 3.2% | 3.6% |
| Civilian labor force B23025 | 26,390 | 101,136 | 352,132 |
| Mean commute (minutes) B08013 | 18.7 | 21.1 | 23.5 |
| Bachelor's degree or higher B15003 | 60.5% | 56.8% | 43.8% |
| Housing units B25001 | 18,079 | 74,888 | 339,042 |
| Owner-occupied B25003 | 41.5% | 63.9% | 73.2% |
| Renters B25003 | 58.5% | 36.1% | 26.8% |
| Median home value B25077 | $444,800 | $439,200 | $316,600 |
| Median gross rent B25064 | $1,649 | $1,646 | $1,234 |
| White, not Hispanic B03002 | 84.1% | 85.5% | 89.9% |
| Black B03002 | 2.9% | 2.3% | 1.1% |
| Hispanic or Latino B03002 | 2.8% | 2.9% | 2.6% |
| Asian B03002 | 4.2% | 4.4% | 1.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Burlington, VT.
Comments